A Prospective, Single-Arm, Phase II Clinical Study Evaluating the Efficacy and Safety of Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Latest Information Update: 23 Feb 2026
At a glance
- Drugs Pirtobrutinib (Primary) ; Sintilimab (Primary) ; Thiotepa (Primary)
- Indications CNS cancer; Lymphoma
- Focus Therapeutic Use
Most Recent Events
- 23 Feb 2026 New trial record